871981-11-2

Upstream product

• 871981-12-3 5-[[(3S)-ethoxy-(2S)-pyrrolidinyl]carbonylamino]levulinic acid methyl ester hydrochloride 
• 501-53-1 benzyl chloroformate 
• 871980-93-7 (1-tert-butoxycarbonyl-(3S)-ethoxy-(2S)-pyrrolidinyl)carboxylic acid 
• 871980-94-8 (1-tert-butoxycarbonyl-(3S)-ethoxy-(2S)-pyrrolidinyl)carboxylic acid methyl ester 
• 871980-96-0 5-[(1-tert-butoxycarbonyl-(3S)-ethoxy-(2S)-pyrrolidinyl)carbonylamino]levulinic acid methyl ester 
• 79416-27-6 methyl aminolevulinate 

Downstream Products

• 871981-13-4 3-[2-(1-benzyloxycarbonyl-(3S)-ethoxy-(2S)-pyrrolidinyl)-5-oxazolyl]propionic acid methyl ester 

Relevant academic research and scientific papers

VLA-4 INHIBITOR

A compound which selectively inhibits bonding between a ligand and α4β1 integrin (VLA-4); a process for producing the compound; and a medicine containing the compound. The compound is one represented by, e.g., the formula (I) or a salt thereof. Also provided is a preventive and/or therapeutic agent which contains the compound or salt as a major component and is effective against diseases attributable to cell adhesion, such as, e.g., inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory intestinal disease, and rejection reaction in transplantation. (In the formula, Y1 represents arylene, etc.; V1 represents aryl, etc.; and R11 to R14 each represents H, OH, halogeno, etc.)